Female sex, non-White race, and longer CAG repeats were associated with earlier SCA6 onset, and earlier SCA27B onset was associated with longer GAA repeats, early concussion, industrial cleaner, pesticide exposure, and herpes simplex virus infection.
Abstract
Objectives
Spinocerebellar ataxias (SCAs) are rare neurodegenerative disorders that arise from genetic sequence variants causing progressive imbalance and motor incoordination. Few studies have investigated nongenetic correlates of patient variation in onset and severity of SCA6 and 27B.
Methods
Participants with genetic diagnosis of SCA6 or SCA27B were recruited from the University of Chicago Medical Center Ataxia Clinic, National Ataxia Foundation, SCA6 Network, and SCA27b Ataxia Foundation to complete an online survey to explore correlates of disease onset and severity. Age at onset was modeled using Cox proportional hazards regression. Disease severity was measured using the Patient-Reported Outcome Measure of Ataxia (PROM-Ataxia) and modeled using ordinal logistic regression.
Results
A total of 282 participants with SCA6 (mean age 64 years, 60% female) and 127 participants with SCA27B were enrolled (mean age 70 years, 47% female). Female sex, non-White race, and longer CAG repeats were associated with earlier SCA6 onset. Earlier SCA27B onset was associated with longer GAA repeats, early concussion, industrial cleaner, pesticide exposure, and herpes simplex virus infection. Less education, non-White race, and lower current alcohol and higher marijuana use were also significantly associated with SCA6 severity.
Discussion
Genetic factors primarily influence SCA6 disease onset, while several environmental exposures are correlated with SCA27B disease onset and severity.
Objectives Spinocerebellar ataxia 27B (SCA27B) is a recently discovered genetic cause of idiopathic late-onset cerebellar ataxia (ILOCA) due to guanine-adenine-adenine (GAA) repeat expansions (greater than 250) in FGF14. We aimed to identify and characterize a New Zealand cohort of patients with SCA27B. Methods Patient...
Sarah C. Anderson, Shilpan G. Patel, M. Rodrigues et al.· Neurology: Genetics· 0 citations
Background Heterozygous GAA-TTC repeat expansions in the FGF14 gene cause spinocerebellar ataxia 27B (SCA27B), a late-onset cerebellar ataxia (LOCA) increasingly recognized in populations of European ancestry. Objective To characterize the clinical and genetic features of SCA27B and compare its phenotype and progressio...
A. Vinagre-Aragón, G. Olmedo-Saura, I. R. Axpe et al.· medRxiv· 0 citations
UBTF-related CONDBA presents with early normal or mildly delayed development followed by regression and progressive ataxia, and elevated NFL may serve as a biomarker of neuronal injury in both humans and animal models.
A. Nagy, A. Luddy, Francine Molay et al.· Journal of Medical Genetics· 0 citations
Background: Spinocerebellar ataxias (SCAs) are progressive neurodegenerative disorders increasingly recognized to have substantial non-motor manifestations. Data regarding these symptoms in the Kashmiri population remain limited.
Objective: To assess the prevalence and pattern of non-motor symptoms among genetically co...
B. Sanaie, S. Tak, Tanveer Hassan et al.· National journal of medical...· 0 citations
Hereditary cerebellar ataxias comprise a heterogeneous group of neurodegenerative disorders with overlapping clinical manifestations, often making accurate bedside diagnosis challenging. Careful clinical phenotyping remains essential to guide targeted genetic testing, particularly in resource limited settings. We retro...
Khyati S. Patel, Nehal M. Shah· International Journal of Res...· 0 citations
Spinocerebellar ataxia 27B (SCA27B; OMIM 620174) is an autosomal dominant late-onset cerebellar ataxia (LOCA) caused by intronic GAA repeat expansions in
FGF14
, first described in 2023. Since its discovery, SCA27B has emerged as a major genetic cause of previously unexplained LOCA across multiple populations. We...
Anish Mehta, Sharvani Gowtham, I. S. M. Giridhar et al.· Annals of Movement Disorders· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.